Ocata Therapeutics Inc fka OCAT

[rocky301]

Clinical trial sites:

Any of the 6 sites PR'd by ACT are respectable institutions that could do the job. In response to mail on "why I feel it might be Casey Eye"...Because there is no clinical site that has been more involved over the past 4 years preparing all of the preclinical studies needed for IND approval. Dr. Raymond Lund has been involved from the start and has even been involved with ACT writing research reports on Long Term Safety of RPE hESC's. Below are just a few links supporting MY notion that Casey would be the logical first choice. No matter who it might me, it is time. In January we were close or had a deal done, otherwise the following would NOT have been inserted in Rabins PR...
"Specific inclusion and exclusion requirements and Investigator contact information will be posted shortly at clinicaltrials.gov. Patients and their caregivers should refer to this source rather than contacting ACT or its representatives."

Casey Eye Institute
(2007)
Advanced Cell Technology, Inc. (OTCBB:ACTC) today announced that it has entered into a sponsored research agreement with Oregon Health and Science University. The Company is collaborating with Dr. Raymond Lund, Dr. Richard Weleber and Dr. Peter Francis at the Casey Eye Institute to conduct preclinical studies for its Retinal Pigment Epithelium ("RPE") Program. Specifically, the research team is conducting a dosage study utilizing the Company's RPE cells in the Royal College of Surgeons ("RCS") rat model and plans to conduct similar studies in other rodent models of retinal degenerative disease. The Company is also in discussions with the Oregon Health and Science University team in regard to future plans for a Phase I human clinical trial.

(2007)
RESEARCH SERVICES AGREEMENT BETWEEN OHSU AND ADVANCED CELL TECHNOLOGY, INC.
http://www.sec.gov/Archives/edgar/data/1140098/000104746907002240/a2176695zex-10_100.htm


TO PRINCIPAL INVESTIGATOR: Raymond Lund

Raymond Lund, Ph.D., a scientific collaborator with ACT, and considered one of the world’s foremost experts in retinal cell physiology and vision restoration, commented, “The study results of ACT’s RPE cells implanted in the various animal models of macular degeneration was phenomenal. If ACT observes even a fraction of that benefit in humans, it will be nothing short of a home run."
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=56967329

(DEC, 2010)
Our research team forged a relationship with Raymond Lund, PhD, considered to be one of the world’s foremost experts in vision restoration and retinal cell physiology, when he was at the Moran Eye Institute and subsequently followed him to the Casey Eye Institute at Oregon Health & Sciences University (OHSU). At OHSU, preclinical “Proof of Concept” and efficacy work was conducted utilizing Dr. Lund’s proprietary Royal College of Surgeons (RCS) rat model for retinal disease.
http://investorshub.advfn.com/boards/read_msg.aspx?message_id=57445243

Long-Term Safety and Function of RPE from Human Embryonic
Stem Cells in Preclinical Models of Macular Degeneration
BIN LU,a CHRISTOPHER MALCUIT,b SHAOMEI WANG,a SERGEJ GIRMAN,a PETER FRANCIS,a LINDA LEMIEUX,b
ROBERT LANZA,b RAYMOND LUNDCasey Eye Institute, Oregon Health and Science University, Portland, Oregon; Advanced Cell Technology,
Worcester, Massachusetts, USA
http://onlinelibrary.wiley.com/doi/10.1002/stem.149/pdf